Oramed Pharmaceuticals Issues Letter to Shareholders
Portfolio Pulse from
Oramed Pharmaceuticals announced a new joint venture, OraTech Pharmaceuticals Inc., focused on oral insulin development. They plan U.S. Phase 3 trials and will distribute a majority of Oramed's holding in OraTech to shareholders as a dividend, coinciding with OraTech's public listing.
March 04, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oramed Pharmaceuticals is launching a joint venture, OraTech, for oral insulin development. They plan to distribute OraTech shares to Oramed shareholders as a dividend, aligning with OraTech's public listing.
The announcement of a joint venture and the distribution of shares as dividends are significant corporate actions that could positively impact Oramed's stock price. The planned public listing of OraTech and the Phase 3 trials add potential value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100